Advertisement

Axillary Lymph Node Tattooing and Targeted Axillary Dissection in Breast Cancer Patients Who Presented as cN+ Before Neoadjuvant Chemotherapy and Became cN0 After Treatment

Published:February 06, 2019DOI:https://doi.org/10.1016/j.clbc.2019.01.013

      Abstract

      Introduction

      Targeted axillary dissection (TAD) is an alternative to axillary dissection for breast cancer patients who presented as cN+ before neoadjuvant chemotherapy (NAC) and became cN0 after treatment. TAD is defined as the removal of sentinel lymph nodes (SLNs) along with the pre-NAC marked positive nodes. Tattooing is an option to mark positive nodes. In this study we aimed to investigate the identification rate of tattooed nodes during surgery, correspondence between tattooed nodes and SLNs, and difficulties and pitfalls of the method.

      Patients and Methods

      In 75 patients who were cN+, with axillary lymph nodes known to have or suspected to have disease were tattooed pre-NAC with a sterile carbon suspension (Spot). After NAC completion all patients became cN0 and underwent TAD as an axillary staging procedure.

      Results

      SLNs were identified successfully in 70 of 75 patients (93.3%). All tattooed nodes were identified successfully intraoperatively in 71 of 75 patients (94.6%). Retrieval of all tattooed nodes in surgical specimens was achieved in 74 patients (98.6%). Correspondence between tattooed nodes and SLNs was observed in 53 of 70 patients (75.3%). In 34 patients (45.3%) the number of pigmented nodes in pathological examination was greater than the number of initially tattooed nodes, indicating the possibility of tattoo ink migration.

      Conclusion

      Tattoo of axillary lymph nodes is a feasible, accurate, and low-cost method of positive node marking pre-NAC. Pathological confirmation of black pigment in the lymph nodes excised is not by itself warranty of retrieval of all marked node because of tattoo ink migration from one node to another. Intraoperative identification using visual inspection is essential.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lyman G.H.
        • Somerfield M.R.
        • Giuliano A.E.
        Sentinel lymph node biopsy for patients with early-stage breast cancer: 2016 American Society of Clinical Oncology clinical practice guideline update summary.
        J Oncol Pract. 2017; 13: 196-198
        • Lyman G.H.
        • Temin S.
        • Edge S.B.
        • et al.
        Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.
        J Clin Oncol. 2014; 32: 1365-1383
        • Giuliano A.E.
        • Hunt K.K.
        • Ballman K.V.
        • et al.
        Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
        JAMA. 2011; 305: 569-575
        • Galimberti V.
        • Cole B.F.
        • Zurrida S.
        • et al.
        Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
        Lancet Oncol. 2013; 14: 297-305
        • Donker M.
        • van Tienhoven G.
        • Straver M.E.
        • et al.
        Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
        Lancet Oncol. 2014; 15: 1303-1310
        • Xing Y.
        • Foy M.
        • Cox D.D.
        • Kuerer H.M.
        • Hunt K.K.
        • Cormier J.N.
        Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.
        Br J Surg. 2006; 93: 539-546
        • Tan V.K.
        • Goh B.K.
        • Fook-Chong S.
        • Khin L.W.
        • Wong W.K.
        • Yong W.S.
        The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer–a systematic review and meta-analysis.
        J Surg Oncol. 2011; 104: 97-103
        • van Deurzen C.H.
        • Vriens B.E.
        • Tjan-Heijnen V.C.
        • et al.
        Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review.
        Eur J Cancer. 2009; 45: 3124-3130
      1. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 3.2018.
        (Available at:) (Accessed December 9, 2018)
        • Boughey J.C.
        • Suman V.J.
        • Mittendorf E.A.
        • et al.
        Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
        JAMA. 2013; 310: 1455-1461
        • Kuehn T.
        • Bauerfeind I.
        • Fehm T.
        • et al.
        Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
        Lancet Oncol. 2013; 14: 609-618
        • Boileau J.F.
        • Poirier B.
        • Basik M.
        • et al.
        Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.
        J Clin Oncol. 2015; 33: 258-264
        • Donker M.
        • Straver M.E.
        • Wesseling J.
        • et al.
        Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
        Ann Surg. 2015; 261: 378-382
        • Caudle A.S.
        • Yang W.T.
        • Krishnamurthy S.
        • et al.
        Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection.
        J Clin Oncol. 2016; 34: 1072-1078
        • Choy N.
        • Lipson J.
        • Porter C.
        • et al.
        Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients.
        Ann Surg Oncol. 2015; 22: 377-382
        • Shin K.
        • Caudle A.S.
        • Kuerer H.M.
        • et al.
        Radiologic mapping for targeted axillary dissection: needle biopsy to excision.
        AJR Am J Roentgenol. 2016; 207: 1372-1379
        • Ruland A.M.
        • Hageman F.
        • Reinisch M.
        • et al.
        Using a new marker clip system in breast cancer: Tumark Vision Clip - feasibility testing in everyday clinical practice.
        Breast Care (Basel). 2018; 13: 116-120
        • Bedi D.G.
        • Krishnamurthy R.
        • Krishnamurthy S.
        • et al.
        Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study.
        AJR Am J Roentgenol. 2008; 191: 646-652
        • Mainiero M.B.
        Regional lymph node staging in breast cancer: the increasing role of imaging and ultrasound-guided axillary lymph node fine needle aspiration.
        Radiol Clin North Am. 2010; 48: 989-997
        • Askin M.P.
        • Waye J.D.
        • Fiedler L.
        • Harpaz N.
        Tattoo of colonic neoplasms in 113 patients with a new sterile carbon compound.
        Gastrointest Endosc. 2002; 56: 339-342
        • Cho Y.B.
        • Lee W.Y.
        • Yun H.R.
        • et al.
        Tumor localization for laparoscopic colorectal surgery.
        World J Surg. 2007; 31: 1491-1495
        • Fisher B.
        • Brown A.
        • Mamounas E.
        • et al.
        Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
        J Clin Oncol. 1997; 15: 2483-2493
        • Bria E.
        • Carbognin L.
        • Furlanetto J.
        • et al.
        Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: sensitivity analysis of randomized trials.
        Cancer Treat Rev. 2014; 40: 847-856
        • Hennessy B.T.
        • Hortobagyi G.N.
        • Rouzier R.
        • et al.
        Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
        J Clin Oncol. 2005; 23: 9304-9311
        • Dominici L.S.
        • Negron Gonzalez V.M.
        • Buzdar A.U.
        • et al.
        Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
        Cancer. 2010; 116: 2884-2889
        • Schneeweiss A.
        • Chia S.
        • Hickish T.
        • et al.
        Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
        Ann Oncol. 2013; 24: 2278-2284
        • El Hage Chehade H.
        • Headon H.
        • El Tokhy O.
        • et al.
        Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients.
        Am J Surg. 2016; 212: 969-981
        • Tee S.R.
        • Devane L.A.
        • Evoy D.
        • et al.
        Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer.
        Br J Surg. 2018; 105: 1541-1552
        • Diego E.J.
        • McAuliffe P.F.
        • Soran A.
        • et al.
        Axillary staging after neoadjuvant chemotherapy for breast cancer: a pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph nodes.
        Ann Surg Oncol. 2016; 23: 1549-1553
        • Plecha D.
        • Bai S.
        • Patterson H.
        • et al.
        Improving the accuracy of axillary lymph node surgery in breast cancer with ultrasound-guided wire localization of biopsy proven metastatic lymph nodes.
        Ann Surg Oncol. 2015; 22: 4241-4246
        • Park S.
        • Koo J.S.
        • Kim G.M.
        • et al.
        Feasibility of charcoal tattooing of cytology-proven metastatic axillary lymph node at diagnosis and sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients.
        Cancer Res Treat. 2018; 50: 801-812
        • He P.S.
        • Li F.
        • Li G.H.
        • et al.
        The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review.
        BMC Cancer. 2016; 16: 107
        • Feng Y.
        • Huang R.
        • He Y.
        • et al.
        Efficacy of physical examination, ultrasound, and ultrasound combined with fine-needle aspiration for axilla staging of primary breast cancer.
        Breast Cancer Res Treat. 2015; 149: 761-765
        • Majid S.
        • Tengrup I.
        • Manjer J.
        Clinical assessment of axillary lymph nodes and tumor size in breast cancer compared with histopathological examination: a population-based analysis of 2,537 women.
        World J Surg. 2013; 37: 67-71
        • Houssami N.
        • Ciatto S.
        • Turner R.M.
        • et al.
        Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla.
        Ann Surg. 2011; 254: 243-251